Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that ...
The FDA has approved a label change on the long-acting injectable contraceptive depot medroxyprogesterone acetate, commonly known as Depo-Provera, to warn users of a potential risk of meningioma. The ...
The FDA approved a label change for Pfizer’s birth control injection Depo-Provera on Dec. 13, adding a warning about the risk of meningioma — a brain tumor — to two versions of the drug. The update ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results